For Immediate Release
Androgens: Clinical Research and Therapeutics, New Open Access Peer-Reviewed Journal, Launching in 2020
Contact: Kathryn Ryan
Androgens: Clinical Research and Therapeutics, a new peer-reviewed, open access journal dedicated to testosterone and other androgens, is now accepting submissions for publication in 2020. The Journal aims to publish the highest-quality peer-reviewed articles from all disciplines of medicine, bringing together the numerous areas of testosterone and other androgens clinical research that previously have been dispersed over multiple specialty journals. Androgens is spearheaded by Editor-in-Chief Abdul Traish, PhD, and Senior Editor Abraham Morgentaler, MD, and is the official journal of the Androgen Society. The journal is supported by an international editorial board of world-renowned researchers and will publish under the Creative Commons Attribution 4.0 (CC-BY and CC-BY-NC) licenses to ensure broad dissemination and participation.
“Though we are very much aware of the current COVID-19 global crisis and the urgency the situation requires, we want to share some positive news with our global research community in announcing the launch of this very important journal.” Says Dr. Abdul Traish, Editor-in Chief. “I am committed to working closely with my colleagues serving on the editorial board, authors, and reviewers across the globe to make this journal the most sought-after resource for scientific and clinical information on testosterone deficiency and its therapy,” says Dr. Traish.
Androgens will publish critical research articles, reviews, case reports, and other contributions related to testosterone deficiency and its treatment in diverse patient populations, including transgender patients, and spanning multiple specialties, such as urology, diabetes, metabolism, and endocrinology.
Dr. Abraham Morgentaler, who is President of the Androgen Society, says the launch of this journal is a “a major achievement for the Androgen Society, which is dedicated to providing excellence in research, education, and clinical practice regarding testosterone deficiency and its treatment.”
Authors are now be able to submit articles to the Journal for consideration. Submit your research today or choose to learn more about the Journal, read its aims and scope, and find submission guidelines on the Androgens website.
About the Publisher
Mary Ann Liebert, Inc., publishers is globally recognized for its authoritative publications. Celebrating its 40th anniversary in 2020, the company is renowned for its prescience in identifying and nurturing critical areas of science and biomedical research. Please visit our website to peruse the publications launched by this privately held company.